MRC1 and neoplasm: Inhibiting MARCO with the monoclonal antibody PY265 supports anti-tumour immunity via pro-inflammatory conversion of TAMs and MDSCs [88], and specific CD206-targeted peptides can likewise support M1-like macrophage phenotype or deliver therapeutics to CD206-expressing TAMs [87, 89].